JP2014516088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516088A5 JP2014516088A5 JP2014514934A JP2014514934A JP2014516088A5 JP 2014516088 A5 JP2014516088 A5 JP 2014516088A5 JP 2014514934 A JP2014514934 A JP 2014514934A JP 2014514934 A JP2014514934 A JP 2014514934A JP 2014516088 A5 JP2014516088 A5 JP 2014516088A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- rvwf
- vwf
- subject
- von willebrand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100036537 von Willebrand factor Human genes 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 35
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 32
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 26
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 26
- 229960001134 von willebrand factor Drugs 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 21
- 108010054218 Factor VIII Proteins 0.000 claims description 18
- 102000001690 Factor VIII Human genes 0.000 claims description 18
- 229960000301 factor viii Drugs 0.000 claims description 18
- 230000002947 procoagulating effect Effects 0.000 claims description 8
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 6
- 208000009292 Hemophilia A Diseases 0.000 claims description 6
- 208000027276 Von Willebrand disease Diseases 0.000 claims description 6
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 4
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 102000004961 Furin Human genes 0.000 claims description 2
- 108090001126 Furin Proteins 0.000 claims description 2
- 208000010287 Type 3 von Willebrand Disease Diseases 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 34
- 229940124597 therapeutic agent Drugs 0.000 claims 34
- 208000015316 von Willebrand disease 3 Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495884P | 2011-06-10 | 2011-06-10 | |
| US61/495,884 | 2011-06-10 | ||
| US201161511901P | 2011-07-26 | 2011-07-26 | |
| US61/511,901 | 2011-07-26 | ||
| US201161523790P | 2011-08-15 | 2011-08-15 | |
| US61/523,790 | 2011-08-15 | ||
| PCT/US2012/041957 WO2012171031A1 (en) | 2011-06-10 | 2012-06-11 | Treatment of coagulation disease by administration of recombinant vwf |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016137381A Division JP6527114B2 (ja) | 2011-06-10 | 2016-07-12 | 組換えフォンウィルブランド因子の投与による凝固疾患の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516088A JP2014516088A (ja) | 2014-07-07 |
| JP2014516088A5 true JP2014516088A5 (https=) | 2015-07-30 |
| JP6347468B2 JP6347468B2 (ja) | 2018-06-27 |
Family
ID=46321496
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514934A Active JP6347468B2 (ja) | 2011-06-10 | 2012-06-11 | 組換えフォンウィルブランド因子の投与による凝固疾患の治療 |
| JP2016137381A Active JP6527114B2 (ja) | 2011-06-10 | 2016-07-12 | 組換えフォンウィルブランド因子の投与による凝固疾患の治療 |
| JP2018246475A Pending JP2019048892A (ja) | 2011-06-10 | 2018-12-28 | 組換えフォンウィルブランド因子の投与による凝固疾患の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016137381A Active JP6527114B2 (ja) | 2011-06-10 | 2016-07-12 | 組換えフォンウィルブランド因子の投与による凝固疾患の治療 |
| JP2018246475A Pending JP2019048892A (ja) | 2011-06-10 | 2018-12-28 | 組換えフォンウィルブランド因子の投与による凝固疾患の治療 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9272021B2 (https=) |
| EP (3) | EP3412305B1 (https=) |
| JP (3) | JP6347468B2 (https=) |
| KR (3) | KR20190041032A (https=) |
| CN (3) | CN107412743B (https=) |
| AR (1) | AR086904A1 (https=) |
| AU (5) | AU2012267458A1 (https=) |
| CA (1) | CA2838845C (https=) |
| DK (3) | DK3858375T3 (https=) |
| ES (3) | ES2682249T3 (https=) |
| FI (1) | FI3858375T3 (https=) |
| HK (1) | HK1257436A1 (https=) |
| HR (1) | HRP20180962T1 (https=) |
| HU (1) | HUE039317T2 (https=) |
| LT (1) | LT2717905T (https=) |
| MX (2) | MX350582B (https=) |
| PL (3) | PL3858375T3 (https=) |
| PT (3) | PT3412305T (https=) |
| RU (2) | RU2680402C2 (https=) |
| SG (2) | SG10201604684WA (https=) |
| SI (1) | SI2717905T1 (https=) |
| TR (1) | TR201808823T4 (https=) |
| WO (1) | WO2012171031A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2682249T3 (es) * | 2011-06-10 | 2018-09-19 | Baxalta GmbH | Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante |
| CN102776260B (zh) * | 2012-07-26 | 2015-04-29 | 上海泰龙生物医药科技有限公司 | 一种高效表达重组人凝血八因子的方法 |
| EP2796145B1 (en) * | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| FR3034669B1 (fr) * | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
| KR102415992B1 (ko) | 2016-04-15 | 2022-07-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 약물동역학 약물 투약 요법을 제공하는 방법 및 장치 |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| CA3069295A1 (en) | 2017-07-07 | 2019-01-10 | Baxalta Incorporated | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf |
| US20190091298A1 (en) * | 2017-07-07 | 2019-03-28 | Baxalta Incorporated | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf |
| WO2019154867A1 (en) | 2018-02-06 | 2019-08-15 | Ablynx Nv | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
| CA3094644A1 (en) * | 2018-03-21 | 2019-09-26 | Baxalta Incorporated | Separation of vwf and vwf propeptide by chromatographic methods |
| US12128090B2 (en) | 2019-02-01 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Methods of prophylactic treatment using recombinant VWF (rVWF) |
| US20220401524A1 (en) | 2019-09-11 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Methods of treatment related to complexes of von willebrand factor and complement c1q |
| KR20220150303A (ko) | 2020-02-04 | 2022-11-10 | 다케다 야쿠힌 고교 가부시키가이샤 | 재조합 vwf의 투여에 의한 중증 폰 빌레브란트병 환자의 월경과다 치료 |
| US20240002861A1 (en) * | 2020-11-24 | 2024-01-04 | Band Therapeutics, Llc | Compositions and methods for treatment of bleeding disorders |
| WO2024124136A1 (en) * | 2022-12-09 | 2024-06-13 | Vega Therapeutics, Inc. | Von willebrand disease animal models |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4638028A (en) | 1985-04-08 | 1987-01-20 | Goodyear Tire & Rubber Company | Rubber polymerases and methods for their production and use |
| JPS62502589A (ja) | 1985-04-11 | 1987-10-08 | ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン | フオン・ビルブラント因子 |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| DE4435485C1 (de) * | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| AT405403B (de) * | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| AT406373B (de) * | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| US6864403B1 (en) | 1998-10-15 | 2005-03-08 | E. I. Du Pont De Nemours And Company | Plant protein disulfide isomerases |
| US20040014657A1 (en) * | 2001-11-05 | 2004-01-22 | Jan Ohrstrom | Use of blood coagulation factor XIII for treating haemophilia A |
| WO2005012354A1 (en) * | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
| EP1593388A1 (en) * | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| CA2591852A1 (en) * | 2004-12-27 | 2006-07-06 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
| EP3653699A1 (en) | 2006-01-04 | 2020-05-20 | Baxalta Incorporated | Oligopeptide-free cell culture media |
| ES2392569T3 (es) * | 2007-06-13 | 2012-12-11 | Csl Behring Gmbh | Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias |
| CA2704234A1 (en) | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
| JP2009127455A (ja) | 2007-11-20 | 2009-06-11 | Bando Kiko Co Ltd | 往復動エンジン |
| CN105816858B (zh) * | 2007-12-28 | 2024-10-18 | 武田药品工业株式会社 | 重组vwf配方 |
| ES2298096B1 (es) * | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| KR101648734B1 (ko) * | 2008-06-24 | 2016-08-18 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체 |
| EP2349314B1 (en) * | 2008-10-21 | 2013-02-27 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| AU2010279463A1 (en) * | 2009-08-04 | 2012-03-01 | Baxter Healthcare S.A. | Transgenic mouse knockout for FVIII and VWF - model of hemophilia A |
| CA2805557A1 (en) | 2010-07-08 | 2012-01-12 | Baxter International Inc. | Method of producing recombinant high molecular weight vwf in cell culture |
| US20120006800A1 (en) | 2010-07-09 | 2012-01-12 | Illinois Tool Works Inc. | Weld bead feature communication systems and devices |
| ES2682249T3 (es) * | 2011-06-10 | 2018-09-19 | Baxalta GmbH | Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante |
-
2012
- 2012-06-11 ES ES12728919.7T patent/ES2682249T3/es active Active
- 2012-06-11 HR HRP20180962TT patent/HRP20180962T1/hr unknown
- 2012-06-11 TR TR2018/08823T patent/TR201808823T4/tr unknown
- 2012-06-11 EP EP18173179.5A patent/EP3412305B1/en active Active
- 2012-06-11 PL PL20216368.9T patent/PL3858375T3/pl unknown
- 2012-06-11 PL PL12728919T patent/PL2717905T3/pl unknown
- 2012-06-11 PT PT181731795T patent/PT3412305T/pt unknown
- 2012-06-11 CN CN201611071108.5A patent/CN107412743B/zh active Active
- 2012-06-11 SG SG10201604684WA patent/SG10201604684WA/en unknown
- 2012-06-11 ES ES20216368T patent/ES2976169T3/es active Active
- 2012-06-11 JP JP2014514934A patent/JP6347468B2/ja active Active
- 2012-06-11 CN CN201280038870.7A patent/CN103732244A/zh active Pending
- 2012-06-11 KR KR1020197010327A patent/KR20190041032A/ko not_active Ceased
- 2012-06-11 SI SI201231321T patent/SI2717905T1/sl unknown
- 2012-06-11 CA CA2838845A patent/CA2838845C/en active Active
- 2012-06-11 PT PT202163689T patent/PT3858375T/pt unknown
- 2012-06-11 MX MX2013014543A patent/MX350582B/es active IP Right Grant
- 2012-06-11 CN CN201810079423.5A patent/CN108210889A/zh active Pending
- 2012-06-11 DK DK20216368.9T patent/DK3858375T3/da active
- 2012-06-11 AU AU2012267458A patent/AU2012267458A1/en not_active Abandoned
- 2012-06-11 EP EP20216368.9A patent/EP3858375B1/en active Active
- 2012-06-11 HU HUE12728919A patent/HUE039317T2/hu unknown
- 2012-06-11 US US13/493,926 patent/US9272021B2/en active Active
- 2012-06-11 EP EP12728919.7A patent/EP2717905B1/en active Active
- 2012-06-11 DK DK18173179.5T patent/DK3412305T3/da active
- 2012-06-11 FI FIEP20216368.9T patent/FI3858375T3/fi active
- 2012-06-11 AR ARP120102073A patent/AR086904A1/es not_active Application Discontinuation
- 2012-06-11 RU RU2017102679A patent/RU2680402C2/ru active
- 2012-06-11 KR KR1020147000709A patent/KR101969515B1/ko active Active
- 2012-06-11 DK DK12728919.7T patent/DK2717905T3/en active
- 2012-06-11 ES ES18173179T patent/ES2860450T3/es active Active
- 2012-06-11 SG SG10202002591QA patent/SG10202002591QA/en unknown
- 2012-06-11 WO PCT/US2012/041957 patent/WO2012171031A1/en not_active Ceased
- 2012-06-11 PT PT127289197T patent/PT2717905T/pt unknown
- 2012-06-11 LT LTEP12728919.7T patent/LT2717905T/lt unknown
- 2012-06-11 PL PL18173179T patent/PL3412305T3/pl unknown
- 2012-06-11 RU RU2014100107A patent/RU2628537C2/ru active
- 2012-06-11 KR KR1020207020667A patent/KR102319868B1/ko active Active
-
2013
- 2013-12-10 MX MX2020000083A patent/MX2020000083A/es unknown
-
2015
- 2015-12-30 US US14/985,212 patent/US20160184403A1/en not_active Abandoned
-
2016
- 2016-04-13 AU AU2016202299A patent/AU2016202299B2/en active Active
- 2016-07-12 JP JP2016137381A patent/JP6527114B2/ja active Active
-
2017
- 2017-07-20 AU AU2017206235A patent/AU2017206235B2/en active Active
-
2018
- 2018-12-27 HK HK18116648.2A patent/HK1257436A1/zh unknown
- 2018-12-28 JP JP2018246475A patent/JP2019048892A/ja active Pending
-
2020
- 2020-01-02 AU AU2020200026A patent/AU2020200026A1/en not_active Abandoned
-
2022
- 2022-03-04 AU AU2022201518A patent/AU2022201518B2/en active Active
-
2025
- 2025-02-28 US US19/067,628 patent/US20250387455A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516088A5 (https=) | ||
| RU2017102679A (ru) | Лечение нарушений свертываемости крови путем введения рекомбинантного фв | |
| Berntorp et al. | Modern haemophilia care | |
| CN103917554B (zh) | 用于改善重构后纯化的因子viii的稳定性的方法 | |
| JP2016514132A5 (https=) | ||
| Federici et al. | Clinical efficacy of highly purified, doubly virus‐inactivated factor VIII/von Willebrand factor concentrate (Fanhdi®) in the treatment of von Willebrand disease: a retrospective clinical study | |
| JP2016516722A5 (https=) | ||
| JP2014530873A5 (https=) | ||
| JP2011527301A5 (https=) | ||
| NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
| EP4255566A1 (en) | Treatment of hemophilia with fitusiran | |
| MX2025012580A (es) | Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal | |
| JP6072810B2 (ja) | 第ｖｉｉｉ因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用 | |
| JP2020526525A5 (https=) | ||
| JP2014530246A5 (https=) | ||
| TW202021611A (zh) | 用於治療再生不良性貧血之醫藥組合物 | |
| Ciccozzi et al. | cAsɛ sruov | |
| JP2015524808A5 (https=) | ||
| AR118608A2 (es) | TRATAMIENTO DE LOS TRASTORNOS DE LA COAGULACIÓN MEDIANTE LA ADMINISTRACIÓN DE UN FACTOR DE VON WILLEBRAND (vWF) RECOMBINANTE | |
| AU2019202876B2 (en) | Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders | |
| JP2019524089A5 (https=) | ||
| WO2004103397A1 (en) | Compositions comprising factor viii and factor ixa for treating haemophilia | |
| MX2024001882A (es) | Metodo para producir factor viii / factor de von willebrand derivado de plasma humano y composicion obtenida. | |
| Huth-Kühne | Cautions and caveats to the treatment of acquired hemophilia A | |
| Franchini | Onset of severe refractory thrombocytopenia following surgery in a patient with type 2B von Willebrand disease—A case report |